These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 1422983

  • 1. Effect of ipriflavone on bone mineral density and calcium-related factors in elderly females.
    Nakamura S, Morimoto S, Takamoto S, Onishi T, Fukuo K, Koh E, Kitano S, Miyashita Y, Yasuda O, Tamatani M.
    Calcif Tissue Int; 1992; 51 Suppl 1():S30-4. PubMed ID: 1422983
    [Abstract] [Full Text] [Related]

  • 2. Comparison of antiresorptive activities of ipriflavone, an isoflavone derivative, and elcatonin, an eel carbocalcitonin.
    Fujita T, Fujii Y, Miyauchi A, Takagi Y.
    J Bone Miner Metab; 1999; 17(4):289-95. PubMed ID: 10575594
    [Abstract] [Full Text] [Related]

  • 3. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E, Lyritis GP, Kosmidis C, Galanos A, Andypas G, Chorianopoulos K, Giagiosis A, Iliadou K, Karagianis A, Katsimichas K, Koskinas A, Matsouka K.
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [Abstract] [Full Text] [Related]

  • 4. Effect of ipriflavone on bone mass in elderly osteoporotic women.
    Passeri M, Biondi M, Costi D, Bufalino L, Castiglione GN, Di Peppe C, Abate G.
    Bone Miner; 1992 Oct; 19 Suppl 1():S57-62. PubMed ID: 1422322
    [Abstract] [Full Text] [Related]

  • 5. Effect of ipriflavone on glucocorticoid-induced osteoporosis in rats.
    Yamazaki I, Shino A, Shimizu Y, Tsukuda R, Shirakawa Y, Kinoshita M.
    Life Sci; 1986 Mar 10; 38(10):951-8. PubMed ID: 3951320
    [Abstract] [Full Text] [Related]

  • 6. Metabolic and bone effects after administration of ipriflavone and salmon calcitonin in postmenopausal osteoporosis.
    Cecchettin M, Bellometti S, Cremonesi G, Solimeno LP, Torri G.
    Biomed Pharmacother; 1995 Mar 10; 49(10):465-8. PubMed ID: 8746073
    [Abstract] [Full Text] [Related]

  • 7. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
    Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S.
    J Bone Miner Res; 2001 Jan 10; 16(1):113-9. PubMed ID: 11149474
    [Abstract] [Full Text] [Related]

  • 8. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
    Hodsman AB, Fraher LJ, Watson PH, Ostbye T, Stitt LW, Adachi JD, Taves DH, Drost D.
    J Clin Endocrinol Metab; 1997 Feb 10; 82(2):620-8. PubMed ID: 9024265
    [Abstract] [Full Text] [Related]

  • 9. Salmon calcitonin in prevention of osteoporosis in maintenance dialysis patients.
    Wang SX, Li H.
    Chin Med J (Engl); 2008 Jul 20; 121(14):1280-4. PubMed ID: 18713548
    [Abstract] [Full Text] [Related]

  • 10. [Effect of salmon calcitonin on bone mineral density and calcium-phosphate metabolism in chronic hemodialysis patients with secondary hyperparathyroidism].
    Matuszkiewicz-Rowińska J, Niemczyk S, Przedlacki J, Puka J, Switalski M, Ostrowski K.
    Pol Arch Med Wewn; 2004 Jul 20; 112(1):797-803. PubMed ID: 15526839
    [Abstract] [Full Text] [Related]

  • 11. Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis.
    Iwamoto J, Takeda T, Sato Y, Uzawa M.
    Yonsei Med J; 2004 Aug 31; 45(4):676-82. PubMed ID: 15344210
    [Abstract] [Full Text] [Related]

  • 12. [Effects of salmon calcitonin in treatment of osteoporosis in patients undergoing dialysis].
    Wang SX, Li H.
    Zhonghua Yi Xue Za Zhi; 2008 Feb 05; 88(6):387-90. PubMed ID: 18581891
    [Abstract] [Full Text] [Related]

  • 13. Ipriflavone improves bone density and biomechanical properties of adult male rat bones.
    Civitelli R, Abbasi-Jarhomi SH, Halstead LR, Dimarogonas A.
    Calcif Tissue Int; 1995 Mar 05; 56(3):215-9. PubMed ID: 7750027
    [Abstract] [Full Text] [Related]

  • 14. Effects of 1-year ipriflavone treatment on lumbar bone mineral density and bone metabolic markers in postmenopausal women with low bone mass.
    Ohta H, Komukai S, Makita K, Masuzawa T, Nozawa S.
    Horm Res; 1999 Mar 05; 51(4):178-83. PubMed ID: 10474019
    [Abstract] [Full Text] [Related]

  • 15. Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial.
    Meier C, Woitge HW, Witte K, Lemmer B, Seibel MJ.
    J Bone Miner Res; 2004 Aug 05; 19(8):1221-30. PubMed ID: 15231008
    [Abstract] [Full Text] [Related]

  • 16. Calcitonin secreting property of ipriflavone in the presence of estrogen.
    Yamazaki I, Kinoshita M.
    Life Sci; 1986 Apr 28; 38(17):1535-41. PubMed ID: 3702590
    [Abstract] [Full Text] [Related]

  • 17. Effects of ipriflavone on bone mass and calcium metabolism in postmenopausal osteoporosis.
    Agnusdei D, Adami S, Cervetti R, Crepaldi G, Di Munno O, Fantasia L, Isaia GC, Letizia G, Ortolani S, Passeri M.
    Bone Miner; 1992 Oct 28; 19 Suppl 1():S43-8. PubMed ID: 1422320
    [Abstract] [Full Text] [Related]

  • 18. Effect of ipriflavone--a synthetic derivative of natural isoflavones--on bone mass loss in the early years after menopause.
    Gennari C, Agnusdei D, Crepaldi G, Isaia G, Mazzuoli G, Ortolani S, Bufalino L, Passeri M.
    Menopause; 1998 Oct 28; 5(1):9-15. PubMed ID: 9689189
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.